Early insulin therapy for type 2 diabetic patients: More cost than benefit

Diabetes Care

Volumn 28, Issue 1, 2005, Pages 222-224

  Davidson, Mayer B ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DIET THERAPY; EDITORIAL; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; INSULIN INFUSION; INSULIN RELEASE; INSULIN TREATMENT; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINOPATHY;

BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; REPRODUCIBILITY OF RESULTS;

EID: 11844302797     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.1.222     Document Type: Editorial

References (32)

1. Davidson MB: The case for control in diabetes mellitus. West J Med 129:193-200, 1978
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. Lebovitz HE: The DCCT and its implications for NIDDM. Clin Diabetes 12:3-4, 1994
4. Davidson MB: Why the DCCT applies to NIDDM patients. Clin Diabetes 12:141-144, 1994
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
6. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
7. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
8. Krolewski AS, Laffel LMB, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332:1251-1255, 1995
9. Warram JH, Scott LJ, Hanna LS, Wantman M, Cohen SE, Laffel LMB, Ryan L, Krolewski A: Progression of microalbuminuria to proteinuna in type 1 diabetes: nonlinear relationship with hyperglycemia. Diabetes 49:94-100, 2000
10. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichire M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
11. Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R: Role of glycemie control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 21:116-120, 1998
12. Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E: Fasting blood glucose: an underestimated risk factor for cardiovascular death: results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 22:45-49, 1999
13. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240, 1999
14. Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycemic threshold for mortality risk? Diabetes Care 22:696-699, 1999
15. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria: Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354:617-621, 1999
16. Wild SH, Dunn CJ, McKeigue, Comte S: Glycemic control and cardiovascular disease in type 2 diabetes: a review. Diabetes Metab Res Rev 15:197-204, 1999
17. Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111:633-642, 2001
18. Malmberg KA, Efendic S, Ryden LE: Feasibility of insulin-glucose infusion in diabetic patients with acute myocaordial infarction: a report from the multicenter trial: DIGAMI. Diabetes Care 17:1007-1014, 1994
19. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wede H: Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction: the DIGAMI Study Group. Eur Heart J 17: 1337-1344, 1996
20. Malmberg K, the DIGAMI (Diabetes Mellitus Infusion in Acute Myocardial Infarction) Study Group: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 13:1512-1515, 1997
21. Stratton IM, Adler AI, Neil HAW, Matthews D, Manley SE, Cull CC, Hadden D, Turner RC, Holman RR, UK Prospective Diabetes Study Group: The Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 321:405-411, 2000
22. Khaw K-T, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycosylated haemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 322:15-18, 2001
23. UKPDS Group: UK Prospective Diabetes Study 6: complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 13:1-11, 1990
24. Harris MI: Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 16: 642-652, 1993
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homoeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
26. UK Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
27. Yki-Jarvinen H: Glucose toxicity. Endocr Rev 13:415-431, 1992
28. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
29. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E: Improved beta cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol (Copsnh) 118:365-373, 1988
30. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng JP: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care. 27:2597-2602
31. Ryan EA, Imes S, Wallace C: Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27: 1028-1032, 2004
32. Peters AL, Davidson MB: Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab 81:2423-2427, 1996